The Severity of COVID-19 in Patients with Hematological and Solid Malignancies: a Sample from Medical City in Baghdad.

Authors

DOI:

https://doi.org/10.32007/jfacmedbagdad.6612086

Keywords:

COVID-19;, Heamopiotic cancer; , Iraqi malignant disease patients; , Medical city complex; , Sold cancer

Abstract

Background: A novel virus known as severe known as severe acute respiratory syndrome coronavirus 2 (SARS-COV-2) primarily targets the respiratory system of infected people. The virus spreads between individuals through respiratory droplets produced during sneezing or coughing. Anyone can contract the virus, but the severity of the disease is often associated with age and pre-existing medical conditions like cancer that may weaken the immune system.

Objectives: In this study, we analyzed severe outcomes of SARS-CoV-2 infections among patients with current or prior malignancy.

Patients and Methods: Between January 1st and December 31st, 2021, a cross-sectional study was conducted on 100 cancer patients from various medical centers in Baghdad, Iraq. The patients included 50% with solid tumors and 50% with hematologic malignancies. The medical centers involved in the study were the Oncology Teaching Hospital, Baghdad Hematological Center, and Private Nursing Home Hospital in the Medical City Complex. The patients were infected with severe acute respiratory syndrome coronavirus 2.

Results: There is a significant correlation between the severity of COVID-19 in cancer patients and their Eastern Cooperative Oncology Group (ECOG) performance status score of ≥1 (10%, P=0.009), the duration of their malignancy being ≥3 years (30%, P=0.017), and the status of their cancer at the time of COVID-19 infection, with patients having was found malignant disease being more likely to develop critical cases. Additionally, patients in remission during their coronavirus infection were found to have developed more critical cases (80%, P=0.001), which was statistically approved.
Conclusion: We found that COVID-19 severity parameters, rather than the underlying malignant disease, are the primary factors in morbidity and mortality

 

Graphical Abstract

Downloads

Download data is not yet available.

References

Andersen KG, Rambaut A, Lipkin WI, Holmes EC, Garry RF. The proximal origin of SARS-CoV-2. Nat Med. 2020;26(4):450-2. https://doi.org/10.1038/s41591-020-0820-9.

Li F. Structure, Function, and Evolution of Coronavirus Spike Proteins. Annu Rev Virol. 2016;3:237-61. https://doi.org/10.1146/annurev-virology-110615-042301.

Taylor D, Lindsay AC, Halcox JP. c or r e sp ondence Aerosol and Surface Stability of SARS-CoV-2 as Compared with SARS-CoV-1. Nejm. 2020;0-2..

Yang Y, Yang M, Shen C, Wang F, Yuan J, Li J, et al. Evaluating the accuracy of different respiratory specimens in the laboratory diagnosis and monitoring the viral shedding of 2019-nCoV infections. Innov. 2020;

https://doi.org/10.1101/2020.02.11.20021493.

Chung M, Bernheim A, Mei X, Zhang N, Huang M, Zeng X, et al. CT imaging features of 2019 novel coronavirus (2019-NCoV). Radiology. 2020; 295(1):202-7. https://doi.org/10.1148/radiol.2020200230.

Ai T, Yang Z, Hou H, Zhan C, Chen C, Lv W, et al. Correlation of Chest CT and RT-PCR Testing for Coronavirus Disease 2019 (COVID-19) in China: A Report of 1014 Cases. Radiology. 2020; 296(2):E32-40.

https://doi.org/10.1148/radiol.2020200642.

Mezalek ZT, Khibri H, Ammouri W, Bouaouad M, Haidour S, Harmouche H, et al. COVID-19 Associated Coagulopathy and Thrombotic Complications. Clin Appl Thromb. 2020; 26. https://doi.org/10.1177/1076029620948137.

Mucha SR, Dugar S, McCrae K, Joseph D, Bartholomew J, Sacha GL, et al. Update to coagulopathy in COVID-19: Manifestations and management. Cleve Clin J Med. 2020;1-10. https://doi.org/10.3949/ccjm.87a.ccc024-up.

Zhang L, Zhu F, Xie L, Wang C, Wang J, Chen R, et al. Clinical characteristics of COVID-19-infected cancer patients: a retrospective case study in three hospitals within Wuhan, China. Ann Oncol. 2020; 31: 894-901. https://doi.org/10.1016/j.annonc.2020.03.296.

Liang W, Guan W, Chen R, Wang W, Li J, Xu K, et al. Cancer patients in SARS-CoV-2 infection: a nationwide analysis in China. Lancet Oncol. 2020; 21:335-7. https://doi.org/10.1016/S1470-2045(20)30096-6.

Yang K, Sheng Y, Huang C, Jin Y, Xiong N, Jiang K, et al. Clinical characteristics, outcomes, and risk factors for mortality in patients with cancer and COVID-19 in Hubei, China: a multicentre, retrospective, cohort study. Lancet Oncol. 2020; 21:904-13. https://doi.org/10.1016/S1470-2045(20)30467-8.

Dai M, Liu D, Liu M, Zhou F, Li G, Chen Z, et al. Patients with cancer appear more vulnerable to SARS-COV-2: a multicenter study during the COVID-19 outbreak. Cancer Discov. 2020;10:783-91.

https://doi.org/10.1158/2159-8290.CD-20-0422.

Garassino MC, Whisenant JG, Huang L-C, Trama A, Torri V, Agustoni F, et al. COVID-19 in patients with thoracic malignancies (TERAVOLT): first results of an international, registry-based, cohort study. Lancet Oncol. 2020; 21:914-22. https://doi.org/10.1016/S1470-2045(20)30314-4.

Shi H, Han X, Jiang N, Cao Y, Alwalid O, Gu J, et al. Radiological findings from 81 patients with COVID-19 pneumonia in Wuhan, China: a descriptive study. Lancet Infect Dis. 2020; 20:425-34.

https://doi.org/10.1016/S1473-3099(20)30086-4.

Guan W-J, Ni Z-Y, Hu Y, Liang W-H, Ou C-Q, He J-X, et al. Clinical characteristics of 2019 novel coronavirus infection in China. N Engl J Med. 2020; 382:1708-20. https://doi.org/10.1056/NEJMoa2002032.

Wang Z, Yang B, Li Q, Wen L, Zhang R. Clinical features of 69 cases with coronavirus disease 2019 in Wuhan, China. Clin Infect Dis. 2020; 71: 769-77.https://doi.org/10.1093/cid/ciaa272.

Wan S, Yi Q, Fan S, Lv J, Zhang X, Guo L, et al. Relationships among lymphocyte subsets, cytokines, and the pulmonary inflammation index in coronavirus (COVID-19) infected patients. Br J Haematol. 2020;189: 428-37. https://doi.org/10.1111/bjh.16659.

Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395:497-506 https://doi.org/10.1016/S0140-6736(20)30183-5.

Chen N, Zhou M, Dong X, Qu J, Gong F, Han Y, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet. 2020; 395:507-13.

https://doi.org/10.1016/S0140-6736(20)30211-7.

Hanna TP, Evans GA, Booth CM. Cancer, COVID-19 and the precautionary principle: prioritizing treatment during a global pandemic. Nat Rev Clin Oncol. 2020;17:268-70. https://doi.org/10.1038/s41571-020-0362-6.

Muhammed Waheeb, Hassan M Abbas, et al. The first 40-days experience and clinical outcomes in the management of coronavirus covid-19 crisis. Single center preliminary study. J Fac Med Baghdad. 2020; 61:4-6. https://iqjmc.uobaghdad.edu.iq/index.php/19JFacMedBaghdad36/article/view/1739

Dockter AG, Angelos GC. Molecular-based alternatives for colorectal cancer screening during the COVID-19 pandemic. Surg Technol Int. 2020; 36:143-7. PMID: 32347964

Mohammed Waheeb Al‐Obaidy, Adnan Mohammed Al Jubouri, et al. Assessment of COVID-19 Treatment containing both Hydroxychloroquine and Azithromycin: A natural clinical trial. International Journal of Clinical Practice.2020; e13856. doi: https://doi.org/10.1111/ijcp.13856

Zacharia BE, Eichberg DG, Ivan ME, Hanft S, Boockvar JA, Isildak H, et al. Letter: surgical management of brain tumor patients in the COVID-19 era. Neurosurgery. 2020; 87:E197-200. https://doi.org/10.1093/neuros/nyaa162

Okwan-Duodu D, Pollack BP, Lawson D, Khan MK. Role of radiation therapy as immune activator in the era of modern immunotherapy for metastatic malignant melanoma. Am J Clin Oncol. 2015;38:119-25

https://doi.org/10.1097/COC.0b013e3182940dc3.

Macarulla T, Pazo-Cid R, Guillén-Ponce C, et al. Phase I/II trial to evaluate the efficacy and safety of nanoparticle albumin-bound paclitaxel in combination with gemcitabine in patients with pancreatic cancer and an ECOG performance status of 2. J Clin Oncol 2019; 37: 230-38. https://doi.org/10.1200/JCO.18.00089

J. Tian, X. Yuan, J. Xiao, Q. Zhong, C. Yang, B. Liu, et al. Clinical characteristics and risk factors associated with COVID-19 disease severity in patients with cancer in Wuhan, China: a multicentre, retrospective, cohort study Lancet Oncol, 21 (2020), pp. 893-903. https://doi.org/10.1016/S1470-2045(20)30309-0

Lee LYW, Cazier JB, Starkey T, Turnbull CD. UK Coronavirus Cancer Monitoring Project Team, Rachel Kerr, Gary Middleton COVID-19 mortality in patients with cancer on chemotherapy or other anticancer treatments: a prospective cohort study. Lancet. 2020; 395:1919-1926.

https://doi.org/10.1016/S0140-6736(20)31173-9.

Liu C, Wang K, Li L, Lv Q, Liu Y, Hu T, Trent JC, Sun B, Hu Q. Severity of COVID-19 in cancer patients versus patients without cancer: a propensity score matching analysis. Journal of Cancer. 2021; 12(12):3558.https://doi.org/10.7150/jca.54205.

Zhang, H.; Han, H.; He, T.; Labbe, K.E.; Hernandez, A.V.; Chen, H.; Velcheti, V.; Stebbing, J.; Wong, K.K. Clinical Characteristics and Outcomes of COVID-19-Infected Cancer Patients: A Systematic Review and Meta-Analysis. J. Natl. Cancer Inst. 2021, 113, 371-380. https://doi.org/10.1093/jnci/djaa168.

Lee LY, Cazier JB, Starkey T, Briggs SE, Arnold R, Bisht V, Booth S, Campton NA, Cheng VW, Collins G, Curley HM. COVID-19 prevalence and mortality in patients with cancer and the effect of primary tumour subtype and patient demographics: a prospective cohort study. The Lancet Oncology. 2020 Oct 1;21(10):1309-16.

https://doi.org/110.1016/S1470-045(20)30442-3

Crolley VE, Hanna D, Joharatnam-Hogan N, Chopra N, Bamac E, Desai M, Lam YC, Dipro S, Kanani R, Benson J, Wilson W. COVID-19 in cancer patients on systemic anti-cancer therapies: outcomes from the CAPITOL (COVID-19 Cancer PatIenT Outcomes in North London) cohort study. Therapeutic advances in medical oncology. 2020 Oct; 12: https://doi.org/10.1177/1758835920971147

Vikas Mehta,,Sanjay Goal, Rafi .K ,et al. Case fatality rate of cancer patients with COVID-19 in a New York hospital system Cancer Discov, 10 (7) (2020), pp. 935-941.

Liu C, Wang K, Li L, Lv Q, Liu Y, Hu T, Trent JC, Sun B, Hu Q. Severity of COVID-19 in cancer patients versus patients without cancer: a propensity score matching analysis. Journal of Cancer. 2021; 12(12):3558.https://doi.org/10.7150/jca.54205.

Vikas Mehta,,Sanjay Goal, Rafi .K ,et al. Case fatality rate of cancer patients with COVID-19 in a New York hospital system Cancer Discov, 10 (7) (2020), pp. 935-941. DOI: https://doi.org/110.1158/2159-8290.CD-20-0516

Lee LY, Cazier JB, Angelis V, Arnold R, Bisht V, Campton NA, Chackathayil J, Cheng VW, Curley HM, Fittall MW, Freeman-Mills L. COVID-19 mortality in patients with cancer on chemotherapy or other anticancer treatments: a prospective cohort study. The Lancet. 2020 Jun 20; 395(10241):1919-26.https://doi.org/10.1016/S0140-6736(20)31173-9.

Mohammed Waheeb AL-Obaidy, Adnan Mohammed Al Jubouri,et al. Presenting the characteristics, smoking versus diabetes, and outcome among patients hospitalized with COVID-19, Journal of Medical Virology.2020; https://onlinelibrary.wiley.com/doi/abs/10.1002/jmv.26487.

Antrim L, Capone S, Dong S, Chung D, Lin S, Wald-Dickler N, In GK. Impact of COVID-19 infection among cancer patients treated at the Los Angeles County Medical Center. Cancer Treatment and Research Communications. 2021 Jan 1; 26: 100273 https://doi.org/10.1016/j.ctarc.2020.100273.

Lima, A.; Sousa, H.; Nobre, A.; Faria, A.L.; Machado, M. The Impact of COVID-19 Pandemic in Portuguese Cancer Patients: A Retrospective Study. Int. J. Environ. Res. Public Health 2021, 18, 8552. https://doi.org/10.3390/ijerph18168552.

Vaduganathan M, Vardeny O, Michel T, McMurray JJV, Pfeffer MA, Solomon SD. Renin-angiotensin-aldosterone system inhibitors in patients with COVID-19. N Engl J Med 2020; 382: 1653-59.

https://doi.org/10.1056/NEJMsr2005760.

COVID-19; Heamopiotic cancer; Iraqi malignant disease patients; Medical city complex; Sold cancer

Downloads

Published

01.04.2024

How to Cite

1.
Abdul Hussein ZA, AL-Obaidy MW, Hashim TM, Al-Khairalla M. The Severity of COVID-19 in Patients with Hematological and Solid Malignancies: a Sample from Medical City in Baghdad. J Fac Med Baghdad [Internet]. 2024 Apr. 1 [cited 2024 Nov. 21];66(1):1-10. Available from: https://iqjmc.uobaghdad.edu.iq/index.php/19JFacMedBaghdad36/article/view/2086

Publication Dates

Similar Articles

1-10 of 1305

You may also start an advanced similarity search for this article.